ReviewInternational journal of nephrology2025
Biomarkers Detecting the Activity of ANCA-Associated Vasculitis: A Systematic Literature Review.
Review in International journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Anti-neutrophil cytoplasmic antibody-associated vasculitis: biological insights and biomarker-guided disease management.Nature reviews. Nephrology · 2026Review
- Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?European journal of immunology · 2026Review
- Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.Clinical reviews in allergy & immunology · 2026Review
- Advances in Diagnosing and Managing Primary Systemic Vasculitides: A Transforming Landscape.Diagnostics (Basel, Switzerland) · 2026Article
- Biomarkers Detecting the Activity of ANCA-Associated Vasculitis: A Systematic Literature Review.International journal of nephrology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) encompasses a group of rare systemic autoimmune diseases characterized by inflammation of small- and medium-sized blood vessels. Despite the efficacy of immunosuppressive therapy in achieving disease remission, a significant proportion of patients experience relapses, underscoring the need for reliable biomarkers to monitor disease activity. This systematic literature review evaluates the potential of urinary and serum biomarkers (CD163, CD206, CD25, and MCP-1) to detect active AAV in adult patients. Method: A comprehensive search on PubMed, Embase, and Cochrane databases identified relevant studies, which were screened and assessed for inclusion based on predefined criteria. Data extraction and quality appraisal were independently conducted using the Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS-2). Results: A total of 20 studies evaluated biomarkers for their diagnostic accuracy in detecting AAV activity. Most articles were scored as moderate risk of bias, with low concerns regarding applicability. Urinary soluble CD163 shows promising diagnostic accuracy for active renal vasculitis, with sensitivity and specificity values ranging from 0.72 to 1 and 0.67 to 0.98, respectively. Serum soluble CD163 and CD206 demonstrated variable accuracy. Serum MCP-1 did not differ between patients in remission and patients with active disease, while urinary MCP-1 showed potential but with inconsistent results across studies. Serum soluble CD25 was significantly elevated in active disease. Some combinations of biomarkers improved diagnostic performance (usCD163 + usCD25 + ssCD25 and usCD163 + serum Calprotectin + hematuria). Conclusion: In conclusion, while usCD163 individually appears to be the most reliable single biomarker for detecting active renal vasculitis in these studies, the heterogeneity of study designs and cutoff values across studies precludes definitive conclusions. Further research is necessary to standardize biomarker use, evaluate promising biomarker combinations, and improve the accuracy of activity monitoring both in renal and extrarenal AAV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.